GlassScriptPhysician profile
Thomas V Connely
NPI 1669462305
$1,544.72
in general payments reported to CMS, 2019-2025
12 companies · $15.27 in 2025
The $15.27 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.04 · 2020: $254 · 2021: $135 · 2022: $207 · 2023: $446 · 2024: $432 · 2025: $15.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.96 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $782.53 | 2020-2025 | |
| Inspire Medical Systems, INC. | $171.67 | 2022-2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $158.63 | 2022-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $92.59 | 2020-2024 | |
| Cochlear Americas | $89.89 | 2023 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Stryker Corporation | $79.66 | 2019-2023 | Na, Smartlock, Scopis Ent |
| Intersect Ent, INC. | $49.99 | 2020-2021 | |
| Optinose US, INC. | $33.35 | 2019-2022 | |
| Acclarent, INC | $25.77 | 2019 | |
| Boston Scientific Corporation | $24.37 | 2024 | Spyglass Discover |
| Smith+Nephew, INC. | $21.95 | 2020 | |
| Glaxosmithkline, LLC. | $14.32 | 2024 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Connely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.